A new article in the Journal of Clinical Oncology (JCO) summarizes the discussions of ASCO’s “Omics and Precision Oncology Workshop,” led by the CancerLinQ Oncology Informatics Task Force (formerly the ASCO Health Information Technology Workgroup), along with the key challenges and recommendations identified by the participants. ASCO held the workshop last October, to begin to address four issues identified at the Data Standards and Interoperability Summit held earlier in the year: omics and precision oncology, advancing interoperability, patient engagement, and value-based oncology.
ASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.
To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.
CancerLinQ LLC, a wholly owned nonprofit subsidiary of ASCO, has announced that Ascension has signed an agreement to participate in the CancerLinQ® platform. Ascension, the largest nonprofit health system in the United States, includes oncology care facilities throughout the country that can benefit from CancerLinQ’s growing quality network.
On June 1 and June 2, CancerLinQ LLC Chief of Strategic Alliances Jennifer L. Wong spoke at the “Big Data in Oncology” session at an ASCO Annual Meeting 2017 seminar titled “The Economics of Cancer Care.”
The CancerLinQ Discovery™ Research & Publications Committee – the volunteer committee charged with reviewing and approving research requests utilizing data from CancerLinQ Discovery™ – will begin accepting proposals on October 1, 2017.
CancerLinQ LLC and the National Cancer Institute (NCI) have announced a partnership to facilitate the exchange of information between CancerLinQ® participating oncology practices and NCI’s Surveillance, Epidemiology, and End Results (SEER) program, one of the primary sources of data on cancer incidence and survival in the United States. The partnership aims to put valuable population-level cancer data at oncologists’ fingertips, while also strengthening the nation’s cancer surveillance efforts through a national data sharing collaboration.
CancerLinQ LLC has announced a long-term partnership with the U.S. Food and Drug Administration (FDA) that will harness cancer patient information and big data analytics to examine the real-world use of emerging and newly approved cancer therapies. Real-world data from CancerLinQ® will be used to grow the knowledge base about patterns of care across all cancer types and therapies, accelerate development of novel insights that might otherwise be challenging to obtain through standard research initiatives and data collection means, as well as potentially inform FDA regulatory strategy and decision-making processes.
CancerLinQ LLC, a wholly owned nonprofit subsidiary of ASCO®, and the National Comprehensive Cancer Network® (NCCN®) have announced a collaboration to provide a link to the NCCN website for easy access to the NCCN Drugs & Biologics Compendium (NCCN Compendium®) within CancerLinQ®. This resource will support CancerLinQ® physicians and provides evidence-based guidance regarding the appropriate use of drugs and biologics in patients with cancer.
CancerLinQ LLC and the Society of Gynecologic Oncology (SGO) have announced a partnership where the SGO will provide expert guidance and insight on the management of gynecologic cancers for the CancerLinQ® platform. CancerLinQ LLC is a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO) that is developing and operating CancerLinQ®, a real-world, big data initiative focused on cancer patient medical information, aimed at improving the quality of patient care and outcomes.
CancerLinQ, LLC CEO, Kevin Fitzpatrick will join leaders of the cancer community including the Cancer Support Community and the American Cancer Society in speaking at the 2017 eyeforpharma Oncology Market Access & Pricing, taking place in Philadelphia.
The American Academy of PAs (AAPA) and CancerLinQ LLC announced today that they will be entering a partnership, with AAPA contributing expertise to the CancerLinQ® platform and potentially leveraging CancerLinQ Discovery™ for queries that will assist research efforts in the PA community aimed at improving the quality of patient care.
On May 22, CancerLinQ LLC Chief of Strategic Alliances Jennifer L. Wong will be speaking at an event hosted by the MIT Enterprise Forum (MITEF) of New York City titled “Outsmarting Cancer: How New Technologies are Tackling a Cure.”
CancerLinQ LLC, a wholly owned nonprofit subsidiary of ASCO®, has announced that Wendy S. Rubinstein, MD, PhD, FACMG, FACP, will be its first Division Director, Clinical Data Management and Curation. Rubinstein will oversee the team working to securely process and analyze the CancerLinQ® platform's patient data from millions of electronic health records to give personalized insights than can improve the quality of care for patients with cancer.
On May 6, leadership from CancerLinQ LLC presented at the Oncology Nursing Society (ONS) Congress in Denver where they delivered a joint presentation on their recent collaboration with ONS and the newly established CancerLinQ® Ambassadors Program – a national practice engagement initiative to drive improved quality and outcomes.
CancerLinQ LLC, a wholly owned nonprofit subsidiary of ASCO, and the College of American Pathologists (CAP) announced today that they will be partnering to bolster the expertise being provided to the CancerLinQ® platform, a real-world, big data initiative focused on cancer patient medical information, aimed at improving the quality of patient care and outcomes.
CancerLinQ LLC, a wholly owned nonprofit subsidiary of the ASCO®, has announced that Santa Clara Valley Medical Center (SCVMC) in San Jose, Calif. has signed an agreement to participate in the CancerLinQ® platform.